RGEN Repligen PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: RGEN
- PE Ratio
The current PE ratio of RGEN can't be determined, as the TTM EPS of -$0.26 is negative. The last recorded PE ratio for Repligen was 741.53 in June 2024.
RGEN PE ratio history
The average historical PE ratio of Repligen for the last ten years is 143.08. Over the past ten years, RGEN's PE ratio was at its highest in the Jun 2024 quarter at 741.53, when the stock price was $126.06 and the EPS was $0.17. The lowest value was in the Mar 2018 quarter, when it reached 48.89 with a price of $36.18 and an EPS of $0.74.
Repligen PE ratio by year
Maximum annual increase: 455.88% in 2023
Maximum annual decrease: -55.54% in 2022
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $143.94 | -$0.46 |
| 2023 | 280.94 | 455.88% | $179.8 | $0.64 |
| 2022 | 50.54 | -55.54% | $169.31 | $3.35 |
| 2021 | 113.67 | -32.38% | $264.84 | $2.33 |
| 2020 | 168.1 | -20.04% | $191.63 | $1.14 |
| 2019 | 210.23 | 51.47% | $92.5 | $0.44 |
| 2018 | 138.79 | 183.07% | $52.74 | $0.38 |
| 2017 | 49.03 | -44.32% | $36.28 | $0.74 |
| 2016 | 88.06 | -12.85% | $30.82 | $0.35 |
| 2015 | 101.04 | 27.58% | $28.29 | $0.28 |
| 2014 | 79.2 | 196.07% | $19.8 | $0.25 |
| 2013 | 26.75 | 95.97% | $13.64 | $0.51 |
| 2012 | 13.65 | N/A | $6.28 | $0.46 |
| 2011 | N/A | N/A | $3.74 | $0 |
| 2010 | N/A | N/A | $4.06 | -$0.13 |
Repligen PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Jun 2025 | N/A | N/A | $124.38 | -$0.26 |
| Mar 2025 | N/A | N/A | $127.24 | -$0.42 |
| Dec 2024 | N/A | N/A | $143.94 | -$0.46 |
| Sep 2024 | N/A | N/A | $148.82 | -$0.14 |
| Jun 2024 | 741.53 | 73.37% | $126.06 | $0.17 |
| Mar 2024 | 427.72 | 52.25% | $183.92 | $0.43 |
| Dec 2023 | 280.94 | 219.8% | $179.8 | $0.64 |
| Sep 2023 | 87.85 | 39.11% | $159.01 | $1.81 |
| Jun 2023 | 63.15 | 4.28% | $141.46 | $2.24 |
| Mar 2023 | 60.56 | 19.83% | $168.36 | $2.78 |
| Dec 2022 | 50.54 | -18.97% | $169.31 | $3.35 |
| Sep 2022 | 62.37 | 10.6% | $187.11 | $3 |
| Jun 2022 | 56.39 | -20.86% | $162.4 | $2.88 |
| Mar 2022 | 71.25 | -37.32% | $188.09 | $2.64 |
| Dec 2021 | 113.67 | -14.25% | $264.84 | $2.33 |
RGEN Price vs fair value
RGEN average PE ratio chart
PE comparison
RGEN PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| NVAX Novavax Inc | 2.96 | $1.25B |
| PFE Pfizer Inc | 14.31 | $139.93B |
| BMY Bristol Myers Squibb Co | 15.65 | $94.6B |
| BMRN Biomarin Pharmaceutical Inc | 19.41 | $10.14B |
| TMO Thermo Fisher Scientific Inc | 32.74 | $213.27B |
| NBIX Neurocrine Biosciences Inc | 35.67 | $15.33B |
| GE General Electric Co | 40.36 | $321.83B |
| TECH BIO-TECHNE Corp | 127.53 | $9.32B |
| CRL Charles River Laboratories International Inc | N/A | $8.25B |
| SGMO Sangamo Therapeutics Inc | N/A | $165.97M |
| RGEN Repligen Corp | N/A | $8.2B |
Frequently asked questions
What is Repligen's PE ratio?
The current price to earnings ratio of RGEN can't be calculated, as its EPS of -$0.26 is negative.
What is the 3-year average PE ratio for Repligen (RGEN)?
Over the last 3 years, the average price to earnings ratio for RGEN stock is 244.61.
What is the 5-year average PE ratio for Repligen (RGEN)?
Over the last 5 years, the average price to earnings ratio for RGEN stock is 170.33.
What is the highest PE ratio for RGEN?
Over the last ten years, the quarterly PE ratio reached a historic high of 741.53 in the Jun 2024 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.